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Abstract
Thrombopoietin (TPO) via signaling through its cognate receptor MPL is a key cytokine involved in the regulation of
megakaryocyte differentiation leading to platelet production. Mature megakaryocytes are polyploid cells that have arrested
DNA replication and cellular proliferation but continue sustained protein synthesis. Here, we show that TPO induces cell-
cycle arrest in the megakaryocytic UT7-MPL cell line by the activation of the ERK/MAPK pathway, induction of p21CIP
transcription, and senescence markers through EGR1 activation. A similar senescence-like process was also detected in
normal primary postmitotic megakaryocytes. In contrast, senescence was not observed in malignant megakaryocytes
derived from primary myelofibrosis patients (a form of chronic myeloid hemopathy). Our data indicate that polyploid
mature megakaryocytes receive signals from TPO to arrest cell proliferation and enter a senescent-like state. An escape from
this physiological process may be associated with certain myeloproliferative neoplasms leading to abnormal
megakaryocytic proliferation.
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Introduction
Hematopoietic stem cells (HSCs) in adults are maintained in a
long term-quiescence state. On rare occasion HSCs may enter the
cell cycle, and their proliferative state is usually coupled to a
differentiation process regulated by both intrinsic and extrinsic
factors such as cytokines (reviewed in [1]). In most somatic cells,
proliferation is dependent on mitogen-activated protein kinase
(MAPK) signaling, shown to be involved in the transition through
the early G1 phase of the cell cycle (reviewed in [2]). Particularly,
prolonged MAPK signaling is also a potent inducer of differen-
tiation and thus links proliferation and developmental progression
in somatic cells [3,4]. However, when mature cells are produced,
they are maintained in a post-mitotic state by mechanisms not yet
fully understood.
Megakaryopoiesis is the hematopoietic differentiation process
that leads to platelet production. The arrest of megakaryocyte
proliferation is followed by ploidization resulting from endomito-
sis. During endomitosis, cell size and protein production per cell
increase. Indeed, endomitosis corresponds to a mitosis with a
failure of late cytokinesis but is still associated with DNA
replication [5,6] and transcription [7]. Usually, when megakaryo-
cytes become 16N, the endomitosis process stops and is followed
by terminal differentiation leading to cytoplasmic fragmentation
and platelet shedding. The main regulator of megakaryocyte
differentiation is the cytokine thrombopoietin (TPO: GeneID:
7066). TPO binds to and activates the TPO receptor (MPL:
GeneID: 4352) signaling to regulate both early and late stages of
differentiation [8].
Cellular senescence is a state of permanent cell-cycle arrest
contributing to tissue aging and has been considered in recent
years as an intrinsic barrier against tumorigenesis (reviewed in
[9–11]). Recently, multiple secreted inflammatory cytokines, their
cognate receptors, and induced transcription factors have been
identified as key mediators of oncogene-induced senescence (OIS)
[12–14]. Besides prevention of tumor outgrowth from benign
lesions, other roles of OIS in non-oncogenic processes are
emerging such as the fibrogenic response to acute tissue damage
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as BRAF
E600 or RAS
V12 and occurs in a variety of cell types
[14,16–18]. OIS is accompanied by an up-regulation of CDK
inhibitors, for instance p15 (GeneID: 1030) (also known as
INK4B), p16 (GeneID: 1029) (also known as INK4A), and p21
(GeneID: 1026) (also known as Cip1), and is associated with an
increase in the senescence-associated b-galactosidase (SA-b-Gal)
activity [19–22]. Moreover, the senescence process is recognized
as a physiologically irreversible mechanism, yet some cancer cells
can escape this process [23,24].
It has been suggested that a possible link between senescence
and terminal differentiation might exist. It is well known that
TPO, via binding to MPL and activation of associated tyrosine
kinase JAK2 (GeneID: 371), induces a high and sustained RAS/
MAPK activation in megakaryocyte precursors and mature
megakaryocytes [4]. Thus we hypothesized that such a mechanism
may be involved in the proliferative arrest observed in mature
megakaryocytes.
Results
The erythro-megakaryocytic cell line UT7 does not naturally
respond to TPO due to very low expression of the TPO receptor
MPL but responds to GM-CSF, a hematopoietic cytokine
mediating its effects on the neutrophil lineage as well as on
hematopoietic progenitors, but it does not appear to have a role in
basal hematopoiesis. The UT7 cell line expresses GM-CSF
receptors and proliferates in response to this cytokine. We
transduced the cells with a retroviral vector encoding MPL and
selected a clone called UT711oc1, which expresses high level of
MPL. Proliferation of UT711oc1 cells was stimulated by GM-CSF
(Figure 1a). Surprisingly, in presence of TPO, UT711oc1 cells
proliferated over a 2-d period before stopping (Figure 1a). This
was a marked difference with the previously described UT7/MPL
cells, which were selected for their growth in presence of TPO [25]
but similar to other previously UT7 cell line described by Porteu
et al. [26]. UT711oc1 cells could be maintained in culture for 3 wk
(unpublished data). These differences are probably related to the
selection processes of the clones: i.e., long term selection at a low
dose of TPO for the UT7/MPL Komatsu’s cells and viral
transduction of mpl for Porteu’s and our cells. These UT711oc1
cells were blocked in the DNA replication process (Figure 1b) and
underwent morphological changes characterized by large cyto-
plasm and nucleus (Figure 1c). Exposure to TPO for 3 d was
sufficient to render the cell unresponsive to further stimulation by
GM-CSF (Figure 1e), suggesting that cell-cycle arrest was not
reversible. Moreover, we did not detect any Annexin V staining in
UT711oc1 cells stimulated with TPO (Figure S1a), nor were the
PARP and caspase 3 cleaved (Figure S1b). On the other hand,
these cells exhibited HP1gamma foci (Figure 1g), SA-b-galactosi-
dase staining (Figure 1d), and expressed cell-cycle inhibitors such
as p21CIP and p27KIP (GeneID: 102) (Figure 1f), as previously
reported [27], 3 senescence-associated markers. These results were
confirmed in two other MPL-overexpressing UT7 cell lines (Figure
S1c). In order to confirm that TPO was able to induce senescence,
other markers of senescence were analyzed. Cathepsin D (GeneID:
1509) mRNA up-regulation has been previously proposed as a
senescence marker [28]. We observed a drastic increase in
cathepsin D mRNA expression in TPO-exposed cells (Figure
S1d). To confirm the senescence phenotype, we determined TPO-
induced gene expression in 24 h TPO-exposed cells relative to that
of GM-CSF-stimulated cells by micro-array analysis. The TPO-
induced gene expression profile was then compared to the
published molecular signature of oncogenic ras-induced senes-
cence [29]. A gene set enrichment analysis (GSEA) comparing
these two sets of genes revealed a significant enrichment for TPO-
induced gene expression in senescent fibroblast genes (Figure 1h).
This enrichment was highly significant for up-regulated genes.
The coincident 30 most up- and down-regulated genes are
depicted (Figure S2). Among the most up-regulated coincident
genes, we found genes involved in inflammation (CXCL2
(GeneID: 292), PTGS2 (GeneID: 574), IL6 (GeneID: 356), IL8
(GeneID: 3576), CXCL3 (GeneID: 2921), IL1B (GeneID: 3553))
that agree with recent literature linking OIS to an interleukin-
dependent inflammatory network and among the most down-
regulated coincident genes appeared genes involved in DNA
replication and cell proliferation. Lastly, senescent cells are able to
secrete cytokines and chemokines. We analyzed TPO-exposed
UT711oc1 supernatant cytokine concentrations compared to GM-
CSF-exposed UT711oc1 supernatant. MCP1 (GeneID: 6347), IL-
1, IL-10 (GeneID: 3586), and VEGF (GeneID: 7422) are secreted
by TPO-exposed cells when compared to GM-CSF stimulated
cells, cytokines previously reported to be secreted by senescent cells
(Figure S1e) [30–33]. There are various types of senescence
including the senescence induced by short telomeres and OIS.
While the first mechanism is linked to long-term culturing, OIS
can quickly be induced in cell lines after small GTPase RAS
overstimulation. TPO has been shown to induce a high and
sustained level of the RAS/MAPK signaling (Figure 1f). Altogeth-
er, these data indicate that TPO per se is able to induce a
senescence process in UT711oc1 cells. We investigated the
implication of MAPK activity in TPO-induced senescence.
In order to determine whether TPO-induced senescence was
RAS/MAPK dependent, we used MAPK pathway inhibitors.
RAS/MAPK inhibition either by PD98059 or U0126 reversed the
TPO-induced cell proliferation arrest (Figure 2a) as previously
reported [4], restored DNA replication (Figure 2b), and decreased
the SA-b-galactosidase staining (Figure 2c), p21CIP level
(Figures 2d and S3a), and cathepsin D expression (Figure S3b)
but did not induce recurrent changes in p27KIP, p53 (GeneID:
7157), or p16INK4a expression (Figure S3c). These results
illustrate that TPO-induced senescence is MAPK-dependent. In
order to clearly demonstrate that the senescence phenotype was a
direct consequence of sustained RAS/MAPK-pathway activation,
we over-expressed a constitutively active form of MEK (MEK1-
S218D/S222D) in UT711oc1 cells and cultured cells in presence
Author Summary
Megakaryocytes are huge bone marrow cells that shed
platelets into the blood stream to promote clotting at sites
of injury. Mature megakaryocytes differentiate from
precursor cells in response to a hormone called thrombo-
poetin. Here, we show that as part of this normal
differentiation process mature megakaryocytes enter a
state called senescence in which cell division stops—a
feature normally associated with cell aging and death. By
studying megakaryocytes in culture, we were able to
determine the biochemical pathway induced by thrombo-
poetin that leads to gene activation associated with
senescence. We conclude that thrombopoietin acts
differently at two steps in megakaryocyte differentiation:
in the early stages it induces megakaryocyte proliferation,
and at a latter stage it arrests the cell division cycle leading
to platelet production by these cells. Interestingly, certain
malignant megakaryocytes did not undergo senescence in
response to thrombopoetin, which might explain the
abnormal proliferation of these cancerous cells.
TPO-Induced Senescence-Like Cell Cycle Arrest
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previously reported [34], a DNA replication arrest (Figure 2f), an
increased SA-b-galactosidase staining (Figure 2g), a rise in the
p21CIP cell-cycle inhibitor transcript (Figure S3d) and protein
(Figure 2h), and an up-regulation of cathepsin D mRNA (Figure
S3e), but it did not affect p27KIP expression (Figure S3f). Of note,
TPO stimulation or active form of MEK did not change total
ERK protein expression (Figure S7). We concluded that TPO-
Figure 1. Thrombopoietin induces cellular senescence of UT711oc1 cells. (a) TPO inhibits UT711oc1 cell proliferation. UT711oc1 cells were
cultured in presence of either GM-CSF or TPO. Viable cells were counted using Trypan blue exclusion. (b) TPO induces a decrease in DNA replication in
UT711oc1 cells. BrdU incorporation was measured in UT711oc1 exposed for 5 d to either GM-CSF or TPO. (c) Morphological changes in TPO-
stimulated UT711oc1 cells. Cells were grown for 5 d in presence of either GM-CSF or TPO and stained with May-Gru ¨nwald Giemsa. (d) SA-b-
galactosidase staining in TPO-treated cells. (e) Irreversible cell-cycle arrest. UT711oc1 cells were grown for 5 d with GM-CSF or TPO and seeded in
methylcellulose with GM-CSF or TPO. Cell colony numbers were determined. (f) Sustained ERK phosphorylation and p21 expression after TPO
exposure. UT711oc1 cells were cultured in presence of GM-CSF or TPO and proteins were analyzed by Western blotting. (g) Formation of
heterochromatin foci in UT711oc1 cells treated with TPO. Cells were grown with either GM-CSF or TPO and heterochromatin protein 1 (HP1) gamma
was revealed by immunofluorescence. (h) GSEA. After 12 h cytokine starvation, UT711oc1 cells were stimulated with either GM-CSF or TPO. TPO-
induced gene expression—relative to GM-CSF—was determined by micro-array analysis and compared by a Gene Set Enrichment Analysis with the
molecular signature of oncogenic ras-induced senescence determined in fibroblasts by Mason et al. [29]. In histograms shown, error bars represent
standard deviations of three independent experiments.
doi:10.1371/journal.pbio.1000476.g001
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activation.
To clarify the implication of cell-cycle inhibitors in TPO-
induced senescence, we knocked down cell-cycle inhibitors
(p27KIP, p21CIP, p16INK4a) and p53 in the UT711oc1 cell
line using lentiviral shRNA expression. Specific shRNAs were
functional at the protein level (Figure 3a). TPO induced a
decrease in cell proliferation and in DNA replication in the
shRNA-expressing cell lines except for p21CIP shRNAs
(Figure 3b and c). Moreover, SA-b-galactosidase staining was
high in all cell lines but in UT711oc1 cells expressing p21CIP
shRNAs (Figure 3d). This demonstrated that TPO-induced
senescence is p21CIP-dependent but p27KIP-, p16INK4a-, and
p53-independent.
We next investigated whether p21CIP was transcriptionally
regulated by the MAPK pathway. We detected significant p21CIP
protein expression 4 h after addition of TPO (unpublished data),
suggesting the possible involvement of a transcription factor
regulated by ERK. Expression of p21CIP is known to be directly
regulated by several transcription factors. We proposed the early
Figure 2. ERK regulates TPO-induced senescence. UT711oc1 cells were cultured for 5 d in presence of TPO and 10 mM of PD98059 or U0126
MAPK inhibitor. MAPK inhibitors (a) restore cell proliferation, (b) increase BrdU incorporation, (c) decrease SA-b-galactosidase activity, and (d) inhibit
ERK phosphorylation and p21 protein expression. UT711oc1 cells were transduced with either empty retroviral vector (pMigr) or the vector encoding
for a spontaneously active MEK (MEK1-SS/DD). MEK1-SS/DD (e) inhibits GM-CSF-dependent cell proliferation, (f) blocks BrdU incorporation, (g)
induces SA-b-galactosidase staining, and (h) causes an increase in ERK phosphorylation and p21 protein expression. Error bar represents the standard
deviation of three independent experiments.
doi:10.1371/journal.pbio.1000476.g002
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for TPO-induced p21CIP-dependent senescence because (i) EGR1
has been implicated in cell-cycle arrest [35], (ii) EGR1 can be
activated by the RAS/MAPK pathway [36], and (iii) EGR1
regulates p21CIP transcription [37]. We first analyzed EGR1
expression in UT711oc1 cells stimulated by either GM-CSF or
TPO and after ERK chemical inhibition. EGR1 was expressed in
UT711oc1 cells only after TPO stimulation. Moreover, its
expression was abrogated by PD98059 and U0126 inhibitors
(Figure 4a). Thus, in UT71oc1 cells, EGR1 expression is regulated
by TPO in a MAPK-dependent mechanism. We analyzed
whether ERK signaling was the main pathway regulating EGR1
expression in our system. UT711oc1 cells infected with a
constitutively active MEK (MEK1-SS/DD) and cultured in
presence of GM-CSF presented an increase in EGR1 expression
(Figure 4b). EGR1 is found either in the cytoplasm or the nucleus.
We studied EGR1 localization after TPO stimulation using
Western blotting (Figure 4c) and immunolabeling coupled with
confocal microscopy (Figure 4d). Based on both these approaches
we showed that EGR1 was localized in the nucleus after 2 h TPO
stimulation and thus was presumably active. To examine whether
EGR1 could regulate p21CIP expression following TPO stimu-
lation, UT711oc1 cells were transduced with lentiviral vectors
expressing EGR1 shRNAs. These shRNAs induced a knockdown
of EGR1 at the mRNA and protein levels (Figures 4e and S4a)
resulting in a decrease in expression of p21CIP after 2 h TPO
stimulation (Figure 4f). Inactivation of EGR1 reversed, at least in
part, the DNA replication arrest of UT711oc1 cells after TPO
exposure (Figure S4b) and decreased the proportion of cells with
SA-b-Galactosidase staining (Figure 4g). In order to demonstrate
that EGR1 directly regulates p21CIP, chromatin immunoprecip-
itation ChIP analysis was performed. Briefly, after EGR1
immunoprecipitation, we detected binding to DNA sequences
belonging to the p21CIP promoter. We observed an increase in
EGR1 binding to p21CIP promoter after TPO stimulation
(Figure 4h). Altogether these results confirmed that after TPO
stimulation EGR1 was activated by the RAS/MAPK pathway,
translocated to the nucleus, bound to p21CIP promoter, and
activated p21CIP transcription, finally inducing senescence.
We studied whether TPO-induced senescence in UT711oc1
cells was a phenomenon widespread to normal megakaryocyte
differentiation. Lin
2 cells isolated from C57/Bl6 mice were
cultured for 6 d with TPO and were found to display a high SA-b-
galactosidase activity (Figure 5a). To extend these findings to
Figure 3. Only p21 knock-down inhibits TPO-induced UT711oc1 cell senescence phenotype. (a) shRNA lentiviral transductions of
UT711oc1 cells are efficient to inhibit, respectively, p21, p27, p53, and p16 in presence of TPO. (b) TPO-stimulated proliferation of p21 shRNA over-
expressing cells is restored. (c) p21 shRNA induces BrdU incorporation in presence of TPO. (d) SA-b-galactosidase staining of p21 shRNA over-
expressing cells decreases. Error bar represents the standard deviation of three independent experiments.
doi:10.1371/journal.pbio.1000476.g003
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+ cells were cultured in vitro in megakaryocytic
differentiation condition. We observed an increase in SA-b-
galactosidase staining 10 to 16 d after the start of the culture
(Figure 5b), when megakaryocytes were polyploid and initiating
platelet production. Cathepsin D mRNA expression was also
induced during megakaryocytic differentiation (Figure S5c). To
determine whether the senescence observed in culture was
associated to cell maturation, we analyzed p21CIP expression
during megakaryocytic cell culture, along with CD41, CD42, and
von Willebrand factor megakaryocytic markers. p21CIP expres-
sion was very low in immature cells (day 0 to day 3 of culture) and
increased at day 6 and day 9. Interestingly, the peak in p21CIP
Figure 4. Transcription factor EGR1 increases and translocates to the nucleus in TPO-stimulated UT711oc1 cells and directly
regulates p21 mRNA expression. (a) TPO-dependent EGR1 induction is inhibited by PD98056 or U0126 treatment. UT711oc1 cells were cultured
for 5 d in presence of TPO and two different MAPK inhibitors. (b) EGR1 increases after MEK1-SS/DD expression in presence of GM-CSF. (c) TPO induces
the translocation of EGR1 to the nucleus. Cells were grown with GM-CSF or TPO for 2 h and lysates were fractionated before being resolved by
Western blotting. (d) Immunolabeling of EGR1 (in red) and nucleus (in blue) were performed and analyzed by confocal microscopy. EGR1 was present
in low quantity in cytoplasm in proliferating UT711oc1 (GM-CSF), but TPO induced an increase in EGR1 labeling and translocation of the transcription
factor to the nucleus. (e) EGR1 shRNA lentiviral transductions efficiently repress EGR1 mRNA expression after TPO exposure and (f) down-regulate
expression of p21. (g) EGR1 knock-down inhibits the SA-b-galactosidase staining. (h) Study of chromatin immunoprecipitation (ChIP) with EGR1
antibody shows enrichment in p21 promoter after TPO exposure compared to GM-CSF. The figures represent one of three performed experiments.
Error bar represents the standard deviation of three independent experiments.
doi:10.1371/journal.pbio.1000476.g004
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level of ERK phosphorylation (Figure 5c). There was a marked
increase in megakaryocyte differentiation measured by the rising
proportion of mature (CD41
+/CD42
+) versus progenitors
(CD41
2/CD42
2) and immature megakaryocytes (CD41
+/
CD42
2) at days 3, 6, and 9 (Figures 5d and S5a). CD41+ cells
were positive for von Willebrand factor (Figure S5b) and this
megakarycocyte differentiation was correlated with the progressive
increase in cathepsin D mRNA expression (Figure S5c). Chemical
inhibition of ERK activation in human megakaryocytic cultures
demonstrated a decrease in p21CIP mRNA and protein
expression (Figure S6a and S6b). To confirm that senescence
Figure 5. Cellular senescence is present in human and mouse mature megacaryocytes but is lacking in oncogenic megakaryocytes.
(a) C57/Bl6 purified Lin
2 were cultured in serum-free medium with 10 ng/mL TPO for megakaryocytic differentiation and stained at day 6 to reveal a
SA-b-galactosidase activity. (b) Human CD34
+ cells were cultured in serum-free medium for 10 d and SA-b-galactosidase activity was detected. (c) ERK
phosphorylation status and p21 expression were analyzed by Western blotting during human megakaryopoiesis at days 0, 3, 6, and 9. (d) Levels of
megakaryocyte maturation membrane markers (CD41
+ and CD42
+) increase during the culture of CD34
+ cells into megacaryocytes. (e) Human
megakaryocytes isolated from healthy bone marrow revealed a SA-b-galactosidase activity. One cell isolated from several present in the original
image is represented. (f) Percentage of SA-b-galactosidase-positive megakaryocytes per sample were analyzed in normal and primary myelofibrosis
megakaryocytes (PMFs). PMFs compared to normal megakaryocytes in culture show a significant decrease in (g) p21 protein expression and (h) p21
mRNA level. Scale bar indicates the sample median. Error bar represents the standard deviation. Each dot represents one PMF or healthy donor
sample.
doi:10.1371/journal.pbio.1000476.g005
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megakaryocyte differentiation, we sorted human mature normal
CD41
+/CD42
+ megakaryocytes from human bone marrow
aspirations and tested these cells for expression of markers of
senescence. Using this approach, we confirmed that SA-b-
galactosidase activity was also present in vivo in mature
megakaryocytes (Figure 5e).
Cellular senescence is a permanent state of cell-cycle arrest and
is emerging as an intrinsic barrier against tumorigenesis. Primary
myelofibrosis (PMF) is a myeloproliferative disorder induced in
50% of cases by an acquired JAK2
V617F mutation leading to
spontaneous kinase activation. In PMF, this mutation is present in
all myeloid cells including the megakaryocytic cell line. Thus, we
investigated whether such malignant megakaryocytes could escape
to TPO-induced physiological senescence. Human PMF and
normal CD34
+ cells were cultured with TPO for 12 d. PMF
compared to normal megakaryocytes exhibited a lower SA-b-
galactosidase staining as revealed by the intensity of staining and
the percentage of SA-b-galactosidase-positive cells (Figure 5f). This
result suggests a defect of TPO-induced senescence in these
malignant megakaryocytes. We examined whether p21CIP was
down-regulated in PMF megakaryocytes and analyzed its
expression in 10 d cultured normal and PMF megakaryocytes.
After 10 d of culture p21CIP mRNA and protein expressions were
lower in PMF than in normal megakaryocytes (Figure 5g and 5h).
The down-modulation of p21CIP expression may play a role in
the resistance to the physiological TPO-induced senescence
process, thus leading to the increase in megakaryocyte hyper-
proliferation in these myeloproliferative diseases.
Discussion
Hematopoietic cytokines are commonly considered as prolifer-
ative and anti-apoptotic proteins regulating blood cell production
in basal or stress conditions. TPO is a specific megakaryocytic
cytokine that induces proliferation and cell differentiation and
regulates platelet production. In addition, in HSCs TPO induces
quiescence of primitive HSCs and proliferation of the multipotent
progenitors. Thus, TPO seems to have proliferative and anti-
proliferative actions, depending on the cell type (reviewed in [38]).
Megakaryopoiesis is a multiple stage differentiation process under
the control of TPO. Megakaryocytic precursors proliferate, switch
to polyploidization, and stop DNA replication before terminal
differentiation leading to platelet shedding. Here, we report that
UT7 cells genetically modified to over-express the TPO receptor
respond to TPO by inducing senescence and that a similar process
occurs in normal megakaryocytes. It was recently demonstrated
that senescence is partially related to the release of inflammatory
cytokines such as IL-6 and IL-8 [13,30,31,33]. Upon secretion by
senescent cells, these cytokines can trigger and maintain the
senescence process. Our observations support the notion that
TPO, a non-inflammatory cytokine, recapitulates the OIS
mechanisms by inducing a high and sustained RAS/MAPK
activation and consequently transcription of EGR1, leading to
synthesis of the p21CIP CDKi. In addition, a recent study suggests
that increased reactive oxygen species (ROS) promote megakar-
yopoiesis [39]. ROS accumulation driving megakaryocyte matu-
ration could also participate in DNA damage observed in
megakaryocytes (cH2AX foci observed in megakaryocytes in our
laboratory) (Ali A and Debili N, unpublished data), cumulative
oxidative damage lastly contributing to cellular senescence
(Figure 6). This TPO-induced senescence could be a key
mechanism for post-mitotic arrest without cell death, allowing
these cells to respond to different stimuli with biological effects
other than proliferation. In this work, we have shown the
important role of p21CIP in the proliferative arrest of the
UT711oc1 cells. Similarly, induction of p21CIP was also found
during megakaryocyte differentiation. It is worth noting that the
mouse knock-out of p21CIP does not abrogate the post-mitotic
arrest during normal megakaryocyte differentiation [40], suggest-
ing the possible involvement of other CDKis, such as p19
INK4d
(GeneID: 1032) [41]. Furthermore, based on our results on
primary cells from healthy donors and from myeloproliferative
patients, it is possible that the heterochromatin changes associated
Figure 6. Schematic representation of transduction pathways potentially involved in TPO-induced senescence phenotype.
doi:10.1371/journal.pbio.1000476.g006
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differentiation. Induction of several CDKis might occur differently
in function of the differentiation stages and allow transmission of
signals in a reversible manner in terminally differentiated
megakaryocytes. It is possible that depending on the stage of
differentiation, there will be differences in MPL and JAK2
expression levels resulting in different levels of TPO-induced
ERK/MAPK signaling.
Senescence is a biological process that limits oncogenic
transformation. Immature hematopoietic cells (progenitors or
HSCs) have a very high proliferative capacity and linking
senescence to proliferation could efficiently limit ‘‘high-risk’’
oncogenic processes in these cells. However, hematopoietic tissues
are still the targets of oncogenic processes (i.e. leukemia and
myeloproliferative disorders). Cancer cells can be defined as cells
that escape the senescence process induced by an oncogene. The
mechanisms leading to such an escape remain unclear. We
hypothesize that in malignant megakaryocytic cells, depending on
MPL signaling for their proliferation, TPO-induced senescence
may be deficient due to events that counteract the MPL/MAPK/
EGR1/p21CIP pathway. In favor of this hypothesis, we found
that PMF megakaryocytes have lost their senescence ability in
response to TPO due to a p21CIP down-expression. The entire
mechanisms leading to such repression of p21CIP expression are
actually not defined.
In conclusion, we describe in this report a mechanism leading to
proliferation arrest in mature hematopoietic cells, the TPO-
induced senescence, that is not operative in malignant megakar-
yocytic cells.
Materials and Methods
Cell Culture
UT711oc1 cells were seeded at a density of 1610
5 cells/mL and
grown in Dulbecco’s modified Eagle’s medium (DMEM; Invitro-
gen, Cergy Pontoise, France) or in methylcellulose medium. Both
media were supplemented with 10% fetal bovine serum (FBS),
antibiotics (100 IU/ml penicillin and 50 mg/ml streptomycin),
and GM-CSF (5 ng/mL) or recombinant human TPO (hTPO)
(10 ng/mL). The MAPK inhibitors PD98059 and U0126 were
used at 10 mM (Calbiochem, San Diego, CA, USA). Human
CD34
+ cells and mouse C57/Bl6 Lin
2 cells were purified and
seeded as previously described [42].
Plasmids and Production of Retroviruses and Lentiviruses
MEK1-S218D/S222D cDNA was cloned into the bicistronic
retroviral vector pMIGR-IRES-GFP. pGIPZ plasmids containing
p21CIP shRNA (no. V2LHS-203118 and V2LHS-230370),
p27KIP shRNA (no. V2LHS-262973), p53 shRNA (no. V2LHS-
217), p16INK4a shRNA (no. V2LHS-195839), and EGR1 shRNA
(no. V2LHS-262011, no. V2LHS-151347, and no. V2LHS-
151348) were purchased from Open Biosystem (Thermo Scientific
products, Surrey, UK). Vesicular stomatitis virus glycoprotein
pseudotyped Viral particles were produced into 293EBNA or 293T
cells as previously described [8,43]. UT711oc1 cells were infected
with concentrated retrovirus or lentivirus supernatants for 2 h at a
multiplicity of infection of 10 and sorted by flow cytometry (FACS
Vantage, BD Biosciences, Mountain View, CA) 48 h later based on
eGFP expression.
GSEA
For microarray analysis, a published data set of senescent
fibroblasts (Mason et al. [29]) was used. Raw global gene
expression values (from Affymetrix GeneChip) for 24 h TPO-
exposed UT711oc1 cells samples and GM-CSF-exposed samples
were collected. We then processed these samples with the robust
multiarray analysis (RMA) algorithm using BioConductor soft-
ware, version 2.3. Using the processed data, GSEA (http://www.
broad.mit.edu/gsea/) was performed to look for enrichment of the
Senescent-fibroblast list. Moreover, gene-array results were
analyzed using Ingenuity Pathways Analysis.
Annexin V Assay
Annexin V fluorescein isothiocyanate (FITC)-positive staining
was determined by FACS analysis according to the manufacturer’s
recommendations (BD Pharmingen, Franklin Lakes, NJ, USA).
Cell-Cycle and CD41/CD42 Analysis
5-Bromo-2-deoxyuridine (BrdU) labeling was performed using
FITC BrdU Flow Kit (BD Biosciences, Le Pont de Claix, France)
according to the manufacturer’s protocol. Cells were labeled
during 30 min with BrdU at 37uC in 5% CO2 atmosphere.
Human cultured CD34
+ cells were rinsed in PBS, stained for
30 min at 4uC with anti-CD41–APC (Allophycocyanin) or anti-
CD42–FITC (BD Biosciences) antibodies. Control cells were
incubated with an irrelevant mouse immunoglobulin G1 (IgG1)
antibody. Cell samples were analyzed by FACS.
Immunoblotting
Proteins were extracted in RIPA buffer with 1% Triton X-100
(Sigma-Aldrich, St. Louis, MO, USA) and supplemented with
protease inhibitor mixture tablets (Complete, Roche Diagnostics,
Meylan, France). Proteins (20–40 mg per lane) were separated on
SDS–polyacrylamide gel electrophoresis and transferred to poly-
vinylidene difluoride (PVDF) membranes by a standard proce-
dure. Antibodies used for immunoblotting were: Actin (Sigma-
Aldrich), p21CIP (no. 2947), p16INK4a (no. 4824), PARP
(no. 9542), phosphoERK (no. 9101), EGR1 (no. 4153) (Cell
Signaling, Beverly, MA, USA), p27KIP (no. 510242) (BD
Biosciences), p53 (no. SC-6243), and Caspase 3 (no. 7148) (Santa
Cruz Biotechnology, Heidelberg, Germany). Bands were revealed
using enhanced chemiluminescence (ECL, Pierce Perbio, Bre-
bie `res, France). The nuclear and cytoplasmic protein separations
were realized as previously described [43].
Quantitative Real-Time PCR
Total RNA was extracted using a Trizol RNA isolation kit
according to the manufacturer’s protocol (Invitrogen). Transcrip-
tion into cDNA was performed using random hexamers and
SuperScript II reverse transcriptase (Invitrogen) according to the
manufacturer’s instructions. All PCR reactions used Taqman PCR
Master Mix (Applied Biosystems, Foster City, CA, USA) to a final
volume of 20 ml. Each cDNA sample was analyzed in triplicate in
the ABI PRISM 7900 Sequence Detection System (Applied
Biosystems).
Immunofluoresence
Fixation and immunofluorescence were performed on
UT711oc1 cells. The following antibodies were used: anti-HP1c
(no. 2619), anti-EGR1 (no. 4153) (cell signaling), and anti-human
Von Willebrand Factor (A0082) (DakoCytomation). The appro-
priate secondary antibodies were conjugated with Alexa 488 or
Alexa 546 (Molecular Probes-Invitrogen, Cergy-Pontoise, France).
TOTO-3 iodide (Molecular Probes) or DAPI was applied for
nucleus staining. Cells were examined under a Zeiss LSM 510
laser scanning microscope (Carl Zeiss, Le Pecq, France) with a
636/1.4 numeric aperture (NA) oil objective.
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Chromatin immunoprecipitations (ChIP) assays were performed
using a ChIP assay kit (cell signaling) with anti-EGR1 Ab (cell
signaling). These assays were performed using UT711oc1
chromatin samples. Quantification of precipitated DNA fragments
was carried out on an ABI PRISM 7000 sequence detection
system using Taqman probes (Eurogentec, Angers, France).
Relative occupancy of the immunoprecipitated factor at a locus
was calculated using the following equation: 2
(CtNegCtl2CtTarget),
where CtNegCtl and CtTarget are mean threshold cycles of
PCR done in duplicate on DNA samples from negative control
ChIP (using non-immune IgG) and targeted ChIP (specific
antibody).
SA-b-Galactosidase
Detection of SA-b-galactosidase activity was performed at
pH=6 as previously described [18].
Cytokines and Chemokines Dosage
UT711oc1 cells were cultured with either GM-CSF or TPO for
6 d and secreted factor concentrations were measured in the
supernatants using Procarta Protein Profiling Assays according to
the manufacturer’s protocol.
Statistical Test
We performed the t test for all experiment. p indicates value of
Student’s t test.
Supporting Information
Figure S1 Thrombopoietin induces cellular senescence
of UT711oc1 and not apoptosis. (a) TPO and GM-CSF
induce similar levels of apoptosis in UT711oc1 cells. Cells were
treated with TPO for 3 and 6 d and compared to GM-CSF-
cultured cells for Annexin V labeling. (b) No difference in PARP
and Caspase 3 cleavage between TPO- and GM-CSF-treated
cells. UT711oc1 were cultured in presence of GM-CSF or TPO as
indicated and PARP and Caspase 3 proteins were analyzed by
Western blotting. The ‘‘W/O Cytokine’’ condition represents 24 h
cytokine starvation and serves as a positive control for PARP and
Caspase 3 cleavage. (c) Two other over-expressing MPL UT7 cell
lines, called clone 5.1 and clone 86, were generated and SA-b-
galactosidase activity was evaluated after 5 d of exposure to TPO
or GM-CSF. (d) TPO up-regulates cathepsin D mRNA. Cells
were exposed to TPO or GM-CSF for 3 to 6 d and cathepsin D
mRNA expression determined by Taqman. (e) UT711oc1 super-
nantants of 48 h TPO-exposed and GM-CSF-exposed cells (1
million cells/ml) were collected and cytokine concentrations were
measured (in pg/ml). Three independent experiments for each
apoptosis assay were performed.
Found at: doi:10.1371/journal.pbio.1000476.s001 (1.55 MB TIF)
Figure S2 Top coincident genes when TPO-induced
gene expression profile was compared to the molecular
signature of oncogenic ras-induced senescence estab-
lished in fibroblasts by Mason et al. [29]. (a) Top coincident
up-regulated genes and their involvement in ‘‘growth, prolifera-
tion, and apoptosis’’; ‘‘inflammation’’; or ‘‘DNA replication,
recombination, and repair,’’ when total coincident genes were
analyzed using Ingenuity Pathways Analysis. (b) Top coincident
down-regulated genes and their involvement in ‘‘growth, prolif-
eration, and apoptosis,’’ ‘‘inflammation,’’ or ‘‘DNA replication,
recombination, and repair.’’
Found at: doi:10.1371/journal.pbio.1000476.s002 (1.96 MB TIF)
Figure S3 p21 mRNA expression is up-regulated by
TPO via the RAS/MAPK pathway. (a) p21 mRNA expression
in UT711oc1 cells. Cells were treated with GM-CSF or TPO in
presence of PD98056 and U0126 inhibitors and assayed for gene
expression by Taqman. (b) Cathepsin D mRNA expression in
UT711oc1 cells. Cells were treated with GM-CSF or TPO in
presence of PD98056 and U0126 inhibitors and assayed for gene
expression by Taqman. (c) p53, p16, and p27 protein expressions
were analyzed by Western blotting. Cells were treated in the same
conditions as in (a). (d) p21 mRNA expression is up-regulated in
UT711oc1 cells over-expressing a spontaneous active form of
MEK (MEK1 SS/DD). (e) Cathepsin D mRNA expression is up-
regulated in UT711oc1 cells over-expressing a spontaneous active
form of MEK (MEK1 SS/DD). (f) p27 protein expression stays
unchanged in presence of active MEK. Error bar represents the
standard deviation of three independent experiments.
Found at: doi:10.1371/journal.pbio.1000476.s003 (1.18 MB TIF)
Figure S4 EGR1 shRNAs are functional and re-induce
cell proliferation after TPO exposure. (a) EGR1 shRNAs
inhibit EGR1 protein expression after TPO exposure. (b) BrdU
incorporation at 5 d of culture shows a significant (but partial)
increase in DNA replication with TPO when cells express EGR1
shRNAs. Error bar represents the standard deviation. We
performed three independent experiments.
Found at: doi:10.1371/journal.pbio.1000476.s004 (0.18 MB TIF)
Figure S5 Cathepsin D and megakaryocytic differenti-
ation markers in normal human megakaryocytes. (a)
Proportion of CD41 and CD42 expressing cells during the
megakaryocytic culture. (b) Co-expression of vWF and CD41
markers in megakaryocytes after 12 d of cell culture. (c) Cathepsin
D mRNA expression during megakaryocytic differentiation
process of human cytapheresis CD34+ cells.
Found at: doi:10.1371/journal.pbio.1000476.s005 (0.66 MB TIF)
Figure S6 Inhibition of ERK decreases p21 expression
in human megakaryocytes. Human megakaryocytes were
cultured for 10 d in presence of TPO and 10 mM of U0126
MAPK inhibitor. U0126 inhibited ERK phosphorylation (b) and
p21 protein (b) and mRNA expression (a). We performed three
independent experiments.
Found at: doi:10.1371/journal.pbio.1000476.s006 (0.11 MB TIF)
Figure S7 TPO and MEK1SS/DD expression induces
ERK phosphorylation without any changes in total ERK
expression. (a) UT711oc1 cells were treated with GM-CSF or
TPO 6 PD98059 or UO126 for 2 d. ERK phosphorylation and
total ERK expression were then evaluated by WB. (b) UT711oc1
cells transduced with either empty retroviral vector (pMigr) or the
vector encoding for a spontaneously active MEK (MEK1-SS/DD)
were cultured in presence of GM-CSF for 3 to 6 d. ERK phospho-
rylation and total ERK expression were then evaluated by WB.
Found at: doi:10.1371/journal.pbio.1000476.s007 (0.16 MB TIF)
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